Track the OnKure Therapeutics, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €164m. The latest transaction was disclosed on 24 March 2026 (Cession). Among the most active insiders: Saccomano Nicholas A. The full history is free.
26
Insider Decl.
n/a
Thresholds
€446,720
1 ops.
Buy Volume
€3m
12 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate OnKure Therapeutics, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$19.50.
42Σ signal
Buys €446,720€3m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,065 sharesClass A Common StockSEC:0001415889-24-024912:1
25 of 26 declarations
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative cancer treatments. It specializes in the discovery and development of targeted therapies to improve patient outcomes.